ReviewEuropean journal of cancer (Oxford, England : 1990)2008
Mesothelin targeted cancer immunotherapy.
Review in European journal of cancer (Oxford, England : 1990), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01413451 (A Single-Dose Pilot Study of Radiolabeled Amatuximab), which is not on this map. Cited by 183 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Who cites it
183 citing papers in PubMed, 1 synthesis or guideline pooled it, 336 citations in OpenAlex.
- Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012Pooled it
- Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.The Lancet. Oncology · 2022Trial
- High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.Oncotarget · 2015Trial
- Review
- Synergistic antitumor activity of CAR-NK cells combined with CAR-macrophages for pancreatic cancer treatment.Genes & genomics · 2026Article
- Mesothelin biology and the evolving landscape of targeted immunotherapy.Molecular therapy. Oncology · 2026Review
- Antibody-Drug Conjugates in Gynecologic Oncology: Advances, Challenges, and Future Directions.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- A DNA Vaccine Incorporating the MHC Class I Trafficking Domain and PADRE Epitope Enhances Antitumor Immunity in a Murine Pancreatic Cancer Model.International journal of molecular sciences · 2026Article
- Preclinical development of mesothelin-targeting CAR T cells for the treatment of cholangiocarcinoma.Hepatology communications · 2026Article
- Oncologic strategies and options for the management of metastatic thymic carcinoma.Mediastinum (Hong Kong, China) · 2026Review
- Oncolytic virus-mediated GPC3 delivery overcomes antigen heterogeneity in hepatocellular carcinoma and enhances GPC3-directed immunotherapy.Frontiers in immunology · 2026Article
- Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation.Molecular cancer · 2025Article
- Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies.Journal for immunotherapy of cancer · 2025Article
- Modern Emerging Biosensing Methodologies for the Early Diagnosis and Screening of Ovarian Cancer.Biosensors · 2025Review
- Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma: Current Progress, Mechanisms of Action, and Challenges.The American journal of pathology · 2025Review
- Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer.Journal for immunotherapy of cancer · 2025Article
- Immunotherapy for small cell lung cancer: the current state and future trajectories.Discover oncology · 2024Review
- Targeted Therapy in Mesotheliomas: Uphill All the Way.Cancers · 2024Review
- Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TC2N.European journal of microbiology & immunology · 2024Article
- Article
123 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Mesothelin is a tumour differentiation antigen that is normally present on the mesothelial cells lining the pleura, peritoneum and pericardium. It is, however, highly expressed in several human cancers including malignant mesothelioma, pancreatic, ovarian and lung adenocarcinoma. The normal biologic function of mesothelin is unknown but recent studies have shown that it binds to CA-125 and may play a role in the peritoneal spread of ovarian cancer. The limited mesothelin expression in normal tissues and high expression in many cancers makes it an attractive candidate for cancer therapy. Three mesothelin targeted agents are in various stages of clinical evaluation in patients. These include SS1P (CAT-5001) a recombinant immunotoxin targeting mesothelin, MORAb-009 a chimeric anti-mesothelin monoclonal antibody and CRS-207 a live-attenuated Listeria monocytogenes vector encoding human mesothelin. These ongoing clinical trials will help define the utility of mesothelin as a target for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.